BIORCHESTRA On Overcoming Challenges For miRNA Therapeutics In Neurodegeneration
Licensing Talks Ongoing
After being selected as an awardee of J&J’s Innovation QuickFire Challenge On Neuroscience in June, Korean bioventure BIORCHESTRA has been attracting attention from the global neuroscience community. CEO Branden Ryu talks to Scrip what makes its technology unique and how it aims to meet major unmet needs in RNA therapeutics and neurodegenerative disorders.
You may also be interested in...
How Do Bioventures Thrive In APAC? Strategies And Risks Beyond Borders
With the global market in sight, several Asian bioventures discussed at BioJapan event recent projects, strategies and challenges in expanding their businesses in APAC. The different characteristics of policies by country and facets of venture capital funding were some of the topics when speakers talked about “what's the ideal collaboration between Asian bioventures?”
KoNECT Talkshow: What Defines Success In New Drug Development?
At a recent conference in Seoul, senior executives shared views on a broad array of topics around developing globally successful new drugs in an extremely competitive environment, including what could be considered as success. Awareness of patient needs and social value emerged as some key threads.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.